Literature DB >> 10992516

Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.

L Kedzierski1, C G Black, R L Coppel.   

Abstract

Plasmodium yoelii merozoite surface protein 4/5 (PyMSP4/5), expressed as a recombinant protein, was highly effective at protecting mice against lethal challenge with P. yoelii. There was a significant correlation between prechallenge antibody levels and peak parasitemia, suggesting that the homologues of PyMSP4/5 in Plasmodium falciparum are promising components of a subunit vaccine against malaria.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10992516      PMCID： PMC101568          DOI： 10.1128/IAI.68.10.6034-6037.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  25 in total

1.  Characterization of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoelii.

Authors:  L Kedzierski; C G Black; R L Coppel
Journal:  Mol Biochem Parasitol       Date:  2000-01-05       Impact factor: 1.759

2.  A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

3.  Immunoglobulin G2a isotype may have a protective role in Plasmodium berghei NK65 infection in immunised mice.

Authors:  B D Akanmori; S Waki; M Suzuki
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

Review 4.  Immune effector mechanisms in malaria.

Authors:  M F Good; D L Doolan
Journal:  Curr Opin Immunol       Date:  1999-08       Impact factor: 7.486

5.  Antimalarial antibodies of the immunoglobulin G2a isotype modulate parasitemias in mice infected with Plasmodium yoelii.

Authors:  W I White; C B Evans; D W Taylor
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

6.  Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.

Authors:  T M Daly; C A Long
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

Review 7.  The immune response to the blood stages of Plasmodium in animal models.

Authors:  J Langhorne
Journal:  Immunol Lett       Date:  1994-07       Impact factor: 3.685

Review 8.  Involvement of T cells in malaria immunity: implications for vaccine development.

Authors:  M F Good; L H Miller
Journal:  Vaccine       Date:  1989-02       Impact factor: 3.641

9.  The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite.

Authors:  I T Ling; S A Ogun; A A Holder
Journal:  Parasite Immunol       Date:  1995-08       Impact factor: 2.280

10.  Immunization against malaria with a recombinant protein.

Authors:  I T Ling; S A Ogun; A A Holder
Journal:  Parasite Immunol       Date:  1994-02       Impact factor: 2.280
View more
  14 in total

1.  Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria.

Authors:  Lina Wang; Lukasz Kedzierski; Steven L Wesselingh; Ross L Coppel
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 2.  Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations.

Authors:  Magdalena Plebanski; Owen Proudfoot; Dodie Pouniotis; Ross L Coppel; Vasso Apostolopoulos; Graham Flannery
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

3.  The Babesia bovis merozoite surface antigen 2 locus contains four tandemly arranged and expressed genes encoding immunologically distinct proteins.

Authors:  Monica Florin-Christensen; Carlos E Suarez; Stephen A Hines; Guy H Palmer; Wendy C Brown; Terry F McElwain
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

4.  Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.

Authors:  L Wang; T L Richie; A Stowers; D H Nhan; R L Coppel
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.

Authors:  Lukasz Kedzierski; Casilda G Black; Matthew W Goschnick; Anthony W Stowers; Ross L Coppel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum.

Authors:  Michelle J Boyle; Christine Langer; Jo-Anne Chan; Anthony N Hodder; Ross L Coppel; Robin F Anders; James G Beeson
Journal:  Infect Immun       Date:  2013-11-11       Impact factor: 3.441

7.  Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.

Authors:  Lina Wang; Matthew W Goschnick; Ross L Coppel
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.

Authors:  Harini D de Silva; Suha Saleh; Svetozar Kovacevic; Lina Wang; Casilda G Black; Magdalena Plebanski; Ross L Coppel
Journal:  Malar J       Date:  2011-09-16       Impact factor: 2.979

9.  Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.

Authors:  M W Goschnick; C G Black; L Kedzierski; A A Holder; R L Coppel
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 10.  Overview of plant-made vaccine antigens against malaria.

Authors:  Marina Clemente; Mariana G Corigliano
Journal:  J Biomed Biotechnol       Date:  2012-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.